Loading
Nanoparticle-based Drug Delivery / Gold and Silver Nanoparticles Synthesis and Applications / Nanoplatforms for Cancer Theranostics · Journal article
Biophysical Reviews · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of advances in gold and silver nanoparticle platforms designed to enhance photodynamic, photothermal, and radiotherapies for breast cancer. The authors synthesize preclinical evidence for how nanoparticle design (size, shape, surface functionalization) can improve light-to-heat conversion, photosensitizer delivery, and radiosensitization, and discuss emerging bimodal and theranostic approaches. However, the authors explicitly state that clinical translation remains challenged by variability in nanoparticle design and incomplete standardization, and that further optimization and rigorous translational studies are required to establish clinical potential.
Narrative review. Breast cancer (addressed as tumor type; no clinical population studied).
Gold and silver nanoparticles enhance plasmonic light-to-heat conversion in photothermal therapy through tunable optical properties dependent on size and shape. Metallic nanoparticles improve photosensitizer delivery, modulate reactive oxygen species generation, and may enhance photodynamic therapy responses through plasmonic effects. High-atomic-number nanomaterials increase local energy deposition and radiosensitization in radiotherapy through physical and biological mechanisms.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies nanoparticle-based approaches as potentially useful tools for precision photon therapies in breast cancer, but emphasizes that preclinical promise has not yet translated to established clinical benefit. Clinicians should recognize that clinical translation remains early-stage and dependent on further standardization and rigorous translational validation.
A narrative review synthesizing preclinical mechanistic work and emerging nanoplatform designs, not reporting original clinical or trial data, and explicitly stating that clinical translation remains challenged and further studies are required.
As stated by the source record.
This review identifies nanoparticle-based approaches as potentially useful tools for precision photon therapies in breast cancer, but emphasizes that preclinical promise has not yet translated to established clinical benefit. Clinicians should recognize that clinical translation remains early-stage and dependent on further standardization and rigorous translational validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Breast cancer (BC) remains a major global health challenge due to tumor heterogeneity, therapeutic resistance, recurrence, and treatment-associated toxicity. Photon-based therapies, including photodynamic therapy (PDT), photothermal therapy (PTT), and radiotherapy (RT), offer spatially controlled approaches for cancer treatment. However, their efficacy can be limited by insufficient selectivity, restricted light penetration, hypoxia, and radioresistance. Metallic nanoparticles (NPs), particularly gold (AuNPs) and silver nanoparticles (AgNPs), have emerged as versatile platforms capable of enhancing photon interactions across the electromagnetic spectrum. This review discusses recent advances in AuNP- and AgNP-assisted photon therapies for BC, emphasizing how NP size, shape, surface functionalization, optical properties, and biological interactions can influence outcomes. In PTT, plasmonic nanostructures enable efficient light-to-heat conversion, whereas in PDT, metallic NPs can improve photosensitizer delivery, modulate reactive oxygen species generation, and may enhance responses through plasmonic effects. In RT, high-atomic-number nanomaterials increase local energy deposition and contribute to radiosensitization through physical and biological mechanisms. Emerging bimodal approaches integrating PDT, PTT, and RT into a single nanoplatform are also discussed as strategies to amplify antitumor responses. Future perspectives highlight next-generation Au and Ag nanoplatforms, including matrix-based delivery systems, hybrid and asymmetric architectures, nanozyme-integrated approaches, and theranostic strategies designed to improve tumor selectivity and clinical translation. Despite encouraging preclinical results, clinical translation remains challenged by variability in NP design and incomplete standardization of irradiation parameters. Overall, Au and Ag nanoplatforms represent promising tools for advancing precision photon-based therapies, although further optimization and rigorous translational studies are required to establish their clinical potential in BC management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.